The ongoing COVID-19 pandemic has had significant global impact on cardiothoracic transplantation. The ISHLT COVID-19 webinar will discuss various aspects of the pandemic on heart and lung transplantation using a case-based approach. Topics include infectivity of SAR-CoV-2, management of wait listed patients infected with or exposed to SARS-CoV-2, summary of recent COVID-19 therapeutic trials and implications for transplant recipients, and lung transplant evaluation and listing criteria for COVID-19 related respiratory failure. Faculty will be available for a live Q&A session.
Fernanda Silveira, MD, and Stephan Ensminger, MD, DPhil
Welcome and Program Panel Introduction
Fernanda Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Case Presentation: Patient on the Waitlist with Persistent Positive PCR
Jonathan Hand, MD, Ochsner Medical Center, New Orleans, LA, USA
Infectivity of SARS-CoV-2
Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada
This talk will discuss the infectiousness and detection of SARS-CoV-2 with respect to incubation period as well as time and severity of illness with a focus on data regarding viral cultures and PCR results.
Waitlist Management of Patients Infected With or Exposed To SARS-CoV-2
Enrico Ammirati, MD, PhD, Asst Grande Ospedale Metropolitano Niguarda, Milan, Italy
The infectiousness of SARS-CoV-2 is of particular clinical relevance in waitlisted candidates with COVID-19 who resolve symptoms of infection but continue to have positive PCRs and the timing of waitlist activation. Additionally, the speaker will discuss inactivation of patients on the waitlist with known exposure to a confirmed case of COVID-19.
Case Presentation: Transplant Recipient With COVID-19
Paola Morejon Barragan, MD, Instituto Argentino de Diagnostico y Tratamiento, Buenos Aires, Argentina
COVID-19 Targeted Therapies
Robin Avery, MD, Johns Hopkins Hospital, Baltimore, MD, USA
This presentation will focus on clinical trials for management of COVID-19 and take home messages from these trials that are pertinent to transplant recipients, as well as recommendations for immunosuppression management (especially if a patient receives dexamethasone).
Case Presentation: Non-Transplant Patient with COVID-19 Related Respiratory Failure
Caroline Patterson, BMBS BMedSci MD, Royal Papworth Hospital, Cambridge, United Kingdom
Lung Transplant for COVID-19
Konrad Hoetzenecker, MD, Medical University of Vienna, Vienna, Austria
This talk will discuss evaluation and listing criteria for patients with COVID-19 related ARDS as well as surgical challenges and post-transplant immunosuppression.
Moderated Q&A Segment with All Speakers
Led by Stephan Ensminger, MD, DPhil, University of Lubeck, Lubeck, Germany
ISHLT COVID-19 Task Force Update
Saima Aslam, MD, MS, UCSD, San Diego, CA, USA
COVID-19 Task Force Chair
Greg Schultz, CEO, ISHLT, Addison, TX, USA
Continuing Education Information
– at the conclusion of this session, attendees will be able to discuss:
- Various aspects of the pandemic on heart and lung transplantation
- The infectiousness and detection of SARS-CoV-2
- Inactivation of patients on the waitlist with known exposure to a confirmed case of COVID-19
- Clinical trials for management of COVID-19 and take-home messages from these trials
- Recommendations for immunosuppression management
- Evaluation and listing criteria for patients with COVID-19 related ARDS as well as surgical challenges and post-transplant immunosuppression
– The target audience for the November webinar session includes physicians, surgeons, scientists, pharmacists, nurses, transplant coordinators and other allied health and social science professionals engaged in the management and treatment of patients with advanced heart or lung disease, basic science or clinical research related to these fields, or other specialties which cause them to become involved in the treatment of patients with advanced heart or lung disease.
Activity Designed to Change
– This activity is designed to change knowledge, competence and performance.
Patient Care and Medical Knowledge
– Current guidelines state that participants in continuing medical and allied health professional education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation or service as Chair/Planner. Disclosures will be distributed in the Learner Notification that you receive as a participant prior to the live virtual session. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.
– The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the ISHLT.
Documenting CME Credits
– The ISHLT provides CME certificates to those who have participated in an ISHLT educational activity. The ISHLT does not submit credits to regulating bodies or certifying organizations on behalf of the participants. It is the participants responsibility to submit proof of credits on his or her own behalf.
Accreditation Statement -
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement –
ISHLT designates this live virtual activity for a maximum of 1.5 AMA PRA Category 1 Credits™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses and Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and The International Society for Heart and Lung Transplantation (ISHLT). Amedco LLC is jointly accredited by the American Council for Continuing Medical Education (ACCME) the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation Statement –
Amedco LLC designates this live activity for a maximum of 1.5 contact hours for nurses.
Amedco LLC has submitted an application to the Accreditation Council for Pharmacy Education (ACPE) for continuing education credits for this activity.
Note to Pharmacists:
The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education.
Transplant Coordinators Credit
As a designated Approved Provider by the American Board for Transplant Certification (ABTC), the International Society for Heart and Lung Transplantation grants up to 1 Category 1 Continuing Education Points for Transplant Coordinators (CEPTCs) for this offering. CEPTC Approval Number: 221-17.